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Background	 Only a limited number of studies have investigated the correlation 
between haematocrit (HCT) and mortality in the general 
population, and few of those studies have had data on a wide 
range of low and high levels of HCT. We investigated the associ­
ation between baseline HCT and mortality in a prospective cohort 
study of 49 983 adult subjects in Iran with a broad spectrum of HCT 
values. 
Methods	 Data on socio-demographic and life-style factors, past medical his­
tory, and levels of HCT were collected at enrollment. During a mean 
follow-up of 5 years (follow-up success rate ~99%), 2262 deaths
were reported. Cox proportional hazards regression models were 
used to estimate hazard ratios and corresponding 95% confidence 
intervals. 
Results	 There was a U-shaped relationship between categories of HCT and 
mortality in both sexes: both low and high levels of HCT were 
associated with increased overall mortality and mortality from car­
diovascular disease. The U-shaped relationship persisted after sev­
eral sensitivity analyses were done, including analyses restricted to 
non-smokers and non-users of opium; analyses excluding deaths 
from accidents and other external causes as well as deaths of per­
sons with self-reported ischemic heart disease at the baseline inter­
view for the study; and analyses excluding the first 2 years of 
follow-up. Self-reported past medical history and lack of data 
about lipids and other cellular blood components were the major 
limitations of the study. 
Conclusions	 Low and high levels of HCT are associated with increased mortality 
in the general population. The findings in the present study can be 
of particular importance for low- and middle-income countries in 
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which a substantial proportion of the population lives with subopti­
mal levels of HCT. 
Keywords	 Anaemia, cancer, cardiovascular disease, erythrocytosis, haematocrit, 
mortality 
Introduction 
An ample body of evidence, including that provided 
by randomized trials and observational studies, exists 
for the association of haematocrit (HCT) or 
haemoglobin (Hb) levels with all-cause mortality, 
disease-specific mortality, or quality-of-life measures 
in specific populations such as the elderly1–3 and pa­
tients with end-stage renal disease,4,5 heart failure,6,7 
cancer,8,9 human immunodeficiency virus (HIV) 
infection/acquired immune deficiency syndrome 
(AIDS),9,10 and inflammatory states such as rheuma­
toid arthritis11,12 or irritable bowel disease.13 Studies 
of HCT in the general population, however, have been 
largely focused on the association of high HCT with 
cardiovascular disease (CVD).14 Most of these studies 
have been conducted in Europe and North America, 
where the proportion of individuals with a suboptimal 
HCT is small, and have therefore been limited by in­
sufficient data for individuals with a low HCT. Thus, 
for example, the lowest category of HCT analysed by 
Kunnas and colleagues in a study of Finnish men was 
that below 44%.15 Few population-based studies have 
investigated the correlation between HCT and mortal­
ity from causes other than CVD.16 
In this paper we report the association between HCT 
and mortality from all causes combined and specific­
ally from CVD and from cancer in men and women 
enrolled in the Golestan Cohort Study (GCS), a large 
prospective cohort study of more than 50 000 adult 
subjects from Golestan Province in northeast Iran. 
The study covers a wide range of values of HCT 
including both high and low levels. 
Golestan Province consists of deserts and mountain­
ous and forested areas, with a climate that is humid 
and moderate. Its population has a socioeconomic 
status ranging from low to intermediate.17 Most of 
the men and women in the province are farmers 
and housewives, respectively.18 The rate of ever 
having smoked cigarettes is moderate among men 
(~38%) and low among women (~2%).19 The chew­ing 
of nass (a tobacco product that is mixed with lime and 
ash) is a relatively common habit practiced chiefly 
among men (~16% of men), particularly in rural 
areas.19 Average body mass index (BMI) in this area is 
high, particularly among women. 20 Studies have 
suggested a low intake of vitamins in rural area of the 
province and among women. 21 The four main causes 
of death in the study population have been (in order): 
cardiovascular diseases, cancer, cere­brovascular 
events, and external causes.22 
Methods 
The GCS is a prospective population-based cohort 
study for which enrollment was conducted between 
January 2004 and June 2008 and included 50 045 par­
ticipants from eastern parts of Golestan Province and 
ranging in age from 40–75 years.19 Our primary goal 
was to recruiting 50 000 healthy individuals (40–75 
years old), with equal numbers of men and women, 
20% from urban areas and 80% of Turkmen ethnicity. 
However, the actual numbers were slightly different 
at the end of recruitment. We report our primary goal 
here because after publication of one of our earlier 
articles from this cohort, some readers thought that 
the difference in proportion of subgroups (e.g. 20% 
urban and 80% rural) was excursively because of dif­
ference in participation rates. Eligibility criteria for the 
study were permanent residence in the study area and 
a negative history of upper gastrointestinal cancer. A 
total of 16 599 urban inhabitants within the specified 
age range for the study were selected randomly from 
Gonbad City, the main urban area in eastern 
Golestan, by systematic clustering based on the 
number of residents in a household. In rural areas, 
all residents of all villages in the study catchment 
area who were within the specified age range were 
invited to participate. In rural areas, recruitment 
took advantage of the network of primary health-care 
centers known as health houses, which are present in 
each group of villages. With participation rates of ap­
proximately 70% for women and 50% for men, the 
GCS enrolled a total of 10 032 urban participants. In 
rural areas, 40 013 participants were enrolled from 
326 villages, with participation rates of 84% for 
women and 70% for men. All participants received a 
personal GCS identification card at the time of enroll­
ment, which allows them to utilize a specialized 
gastrointestinal clinic established by the study group 
in the study area, and provides free services for GCS 
participants if they experience any gastrointestinal 
symptoms. 
At baseline, and after obtaining written informed 
consent from prospective participants, trained nurses 
and physicians collected data on their demographic 
characteristics and several life-style factors in 
face-to-face interviews and through the use of a 
structured questionnaire. Additionally, members of 
the study staff measured anthropometric indices and 
blood pressure (BP). To identify deceased persons 
within the cohort and to ascertain the causes of 
their death, all participants in the GCS are actively 
followed through annual telephone calls and by 
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local health workers in their communities, and 
through a review of monthly provincial death regis­
tration reports. When the death of a GCS participant 
is reported, a validated verbal autopsy questionnaire23 
is completed through an interview of the closest rela­
tive of the deceased, and copies of all available and 
relevant medical documents for deceased cohort 
members are collected from hospitals and pathology 
laboratories in Golestan and neighbouring provinces. 
All collected documents are reviewed by at least 
two expert physicians to determine the cause of 
death. Further details on the design of GCS and 
ascertainment of causes of death are provided else­
where.19,23 The success rate of the follow-up in the 
GCS has been ~99%. The high telephone coverage; a 
low immigration rate, particularly of persons in the age 
range of the study participants; the ability to con­tact 
local health workers in rural areas and free ser­vices 
provided in the GCS for the management of 
gastrointestinal diseases may be among the factors 
that contributed to high success rate of the follow-up. 
Individuals examined for enrollment in the GCS 
were considered tobacco users if they had smoked 
cigarettes, a water pipe (hookah), or a pipe, or had 
used nass at least once a week for a period of 6 
months or more. Cigarette smokers who smoked 
during the year before the enrollment interview 
were classified as current cigarette smokers and 
those who smoked 520 cigarettes/day during the 
year before the interview were considered current 
heavy smokers. Opium users were defined as persons 
who had consumed opium at least once a week for at 
least 6 months. The self-reported use of tobacco and 
opium is a reliable and valid indicator of exposure to 
these substances in this population.24 Body mass 
index (BMI) was calculated by dividing body weight 
(kg) by the squared value of height (m). Participants 
were considered hypertensive if they used 
anti-hypertensive medication or fulfilled the criteria 
of having a systolic blood pressure 5140 mm Hg or 
a diastolic blood pressure above 590 mm Hg.25 Data
on chronic conditions, such as diabetes and ischemic 
heart disease (IHD), were obtained using pre-specified 
questions and defined as self-reported diagnoses 
made by a physician. 
Values of HCT were determined in blood samples 
obtained at the time of baseline interviews for the 
GCS. For the determination of HCT, venous blood 
was well and immediately mixed with ethylene di­
amine tetra-acetic acid (EDTA). Anticoagulated 
blood was drawn into microhaematocrit tubes, 
which were filled to approximately 75% of capacity 
and centrifuged for 10 minutes. The values of HCT 
were determined with an HCT reader. To eliminate 
the effect of outliers, value of HCT of <15% 
and 570% were excluded from the study analyses. 
Values of HCT were categorized in units of 5%, 
except for the lowest and highest categories, which 
included HCTs of 15%–29% and 55%–69%, 
respectively, because of the small number of partici­
pants with these values of HCT. According to the 
World Health Organization’s (WHO) definition for in­
dividuals 515 years of age, the threshold values of 
hemoglobin (Hb) below which individuals are con­
sidered anemic are 13 g/dl (~HCT 39%) for men and 12 
g/dl (~HCT 36%) for non-pregnant women.26 The 
practical definition of erythrocytosis (an abnormally 
high HCT) consistent with the WHO threshold for 
white persons (Caucasians) is an Hb 518.5 g/dl (~HCT 
55%) in men or 516.5 g/dl (~HCT 50%) in women for 
Caucasians.27 The ‘normal’ range of HCT values may 
differ across populations28; among the commonly used 
ranges are 40–50% for men and 36–44% for women. 29 
In the analyses done for the GCS, men with HCTs of 
35–39% and women with HCTs of 40–44% were 
assigned as reference groups. 
The GCS was approved by the institutional review 
boards of the Digestive Disease Research Center of 
Tehran University of Medical Sciences, the US 
National Cancer Institute (NCI), the World Health 
Organization International Agency for Research on 
Cancer (IARC), and the Mount Sinai School of 
Medicine. 
Statistical analysis 
In the analysis of the study data, numbers and 
percentages were calculated and presented for cat­
egorical variables, and means and standard deviations 
(SD) for continuous variables. Multivariate linear-
regression models were used to investigate correlates 
of HCT levels in men and women separately. In these 
models, HCT was included as a continuous variable, 
and adjusted mean HCT values (predicted by the 
models) for categorical variables and regression coef­
ficients for continuous variables were calculated, 
along with corresponding P values. Values of P for 
trend were obtained from the same models by assign­
ing consecutive numbers to categories within each 
categorical variable. 
Cox proportional-hazards regression models were 
used to estimate hazard ratios (HRs) and correspond­
ing 95% confidence intervals (CIs) for the association 
between categories of HCT and mortality, separately 
for men and women. The HRs (95% CIs) were ad­
justed for age; ethnicity (Turkmen, other); place of 
residence (Gonbad City, rural areas); education 
level; cigarette smoking (both never/current/former 
status and cumulative use); water-pipe smoking; 
chewing of nass; opium use; BMI; hypertension; and 
self-reported diabetes, IHD, and cancer (excluding 
upper gastrointestinal cancers, because these cancers 
were among the exclusion criteria in the study). 
Sensitivity analyses were done by excluding ever-
smokers of cigarettes or hookahs and opium users 
(because tobacco smoking and opium use have been 
shown to be associated with a higher mortality in this 
population22; cases of death during the first 2 years of 
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follow-up; cases of death from external causes (e.g., 
suicide, burns, and vehicle or other accidents); and 
persons with self-reported IHD at the baseline inter­
view. As additional procedures we repeated our ana­
lyses after considering cardiovascular and cancer 
mortality as outcomes representing failure of interest. 
When there was only a single case of death in a cat­
egory, the category was combined with the next cat­
egory; when there was no next category, the category 
in which the death occurred was combined with the 
previous category. 
We used likelihood ratio tests to compare and test 
for goodness of fit of adjusted linear vs. nonlinear 
models. We compared two models, one with HCT 
alone as a continuous variable and the other with 
linear plus squared and cubed terms of HCT. The 
latter model showed a better fit, with P < 0.0001 for 
both women and men, and we therefore used frac­
tional polynomial terms in the multivariate Cox 
proportional-hazards models to investigate the 
non-linear association between HCT and mortality. 
The variables included in these models were the 
same as those in the Cox proportional-hazards 
models described above, but HCT was used as a con­
tinuous rather than as a categorical variable. The 
powers for fractional polynomials were chosen from 
the set of -2, -1, -1/2, 0, 1/2, 1, 2, and 3, in which 
the power of 0 refers to the natural logarithm, based 
on the best fit to the data.30 All statistical analyses 
were done with STATA statistical software version 11 
(Stata, College Station, TX, USA). All reported values 
of P are two-sided, and P < 0.05 was considered stat­
istically significant. 
Results 
Of the 50 045 cohort participants, 62 (0.1%) were 
excluded from the GCS because their HCT levels 
were out of the selected range (15%–69%) or were 
missing. The characteristics of the remaining 49 983 
participants, and the distribution of HCT values mea­
sured at baseline, are summarized in Table 1. A total 
of 7.9% of the women in the study had an HCT < 35% 
and 12.1% had an HCT 5 45%. The proportions of 
men with an HCT < 40% or 5 50% were 15.1% and 
7.3%, respectively. 
A total of 955 women and 1307 men died during a 
mean follow-up of 5 years. For both men and women 
there was a U-shaped relationship between HCT and 
overall mortality (Table 2), although the association 
between a high HCT and mortality was stronger in 
women than in men. As compared with respective 
unadjusted risk estimates, the adjusted estimates 
were slightly higher for women but lower for men. 
The main covariates responsible for these differences 
were age (the main effect in cases of a low HCT) and 
hookah smoking (the main effect in cases of a high 
HCT) in women, and age (for both a low and a high 
HCT), hypertension (for a high HCT), and cigarette 
smoking status (for a high HCT) in men. The results 
for mortality related to CVD and for mortality related 
to cancer were slightly stronger in both men and 
women as compared to the results for overall 
mortality. 
Exclusion of the first 2 years of follow-up reduced 
the strength of the association between mortality and 
a low HCT in both men and women (Table 3); in 
men, the association of mortality with a high HCT 
was no longer apparent, whereas in women it was 
still present but more weakly so. An analysis re­
stricted to never-users of cigarettes, a hookah, or 
opium resulted in a stronger association between 
overall mortality and an increased HCT in men. 
Excluding external causes of death and participants 
with self-reported IHD at the baseline interview had 
relatively little effect on the results for HCT and 
mortality. 
The results of fractional polynomial analyses using 
HCT as a continuous variable also showed a U-shaped 
association between HCT and mortality in both the 
overall analyses (Figure 1) and after exclusion of 
the first 2 years of follow-up (Figure 2) for men 
and women. 
The correlates of HCT level are shown in Table 4. 
The strongest predictor of HCT was smoking, and par­
ticularly current heavy smoking, with the mean HCT 
of current heavy smokers being 1.54 units higher than 
that of never-smokers. There were smaller but statis­
tically significant differences among the levels of 
other predictors of HCT. Whereas older age was posi­
tively correlated with higher HCT in women, there 
was an inverse association in men. Men and women 
of Turkmen ethnicity and participants residing in 
urban areas had higher HCTs than those of other 
ethnicities and those residing in rural areas, respect­
ively. Education showed an inverse association with 
HCT for both men and women. Ever-smoking of a 
hookah, BMI, and hypertension were associated 
with a higher HCT in both sexes. Self-reported dia­
betes was associated with a higher HCT in women 
only. The results of a polynomial logistic regression 
analysis of correlates of HCT as a categorical variable 
were consistent with those of the linear regression 
models reported above (the method used in the logis­
tic regression models is shown in the footnote to 
Supplementary Table 1, available as Supplementary 
data at IJE online). 
Discussion 
In the population in northeastern Iran in which the 
GCS is being conducted, there appears to be a 
U-shaped relationship between HCT and mortality, 
with both low and high values of HCT being asso­
ciated with increased overall and cardiovascular mor­
tality. This relationship was observed for both men 
and women, after controlling for a self-reported his­
tory of IHD, diabetes, and cancer at the baseline of 
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Table 1 Characteristics of baseline cohort of study populationa 
Characteristic Women Men Both sexes 
Total 28 776 (100) 21 207 (100) 49 983 (100) 
Age (years) 51.3 (8.6) 53.2 (9.4) 52.1 (9.0) 
Ethnicity 
Non-Turkmen 7595 (26.4) 5175 (24.4) 12 770 (25.5) 
Turkmen 21 181 (73.6) 16 032 (75.6) 37 213 (74.5) 
Place of residence 
Rural 22 692 (78.9) 17 287 (81.5) 39 979 (80.0) 
Urban 6084 (21.1) 3920 (18.5) 10 004 (20.0) 
Education level 
No school 24 673 (85.7) 10 406 (49.1) 35 079 (70.2) 
Primary school 2909 (10.1) 5543 (26.1) 8452 (16.9) 
Middle school 455 (1.6) 1785 (8.4) 2240 (4.5) 
High school/higher 739 (2.6) 3473 (16.4) 4212 (8.4) 
Cigarette smoking 
Never smoker 28 338 (98.5) 13 057 (61.6) 41 395 (82.8) 
Former smoker 133 (0.4) 3572 (16.8) 3705 (7.4) 
Current light smoker 249 (0.9) 2724 (12.8) 2973 (6.0) 
Current heavy smoker 56 (0.2) 1854 (8.7) 1910 (3.8) 
Cumulative use of cigarettes 
1–5 pack-years 293 (1.0) 2471 (11.7) 2764 (5.5) 
5.1–10 pack-years 60 (0.2) 1200 (5.6) 1260 (2.5) 
10.1–20 pack-years 46 (0.2) 1751 (8.3) 1797 (3.6) 
420 pack-years 39 (0.1) 2713 (12.8) 2752 (5.5) 
Water-pipe smoking 
Never 28 418 (98.8) 21 010 (99.1) 49 428 (98.9) 
Ever 345 (1.2) 187 (0.9) 532 (1.1) 
Nass chewing 
Never 28 477 (99.0) 17 727 (83.6) 46 204 (92.4) 
Ever 299 (1.0) 3476 (16.4) 3775 (7.6) 
Opium use 
Never 26 421 (91.8) 15 066 (71.1) 41 487 (83.0) 
Ever 2352 (8.2) 6139 (28.9) 8491 (17.0) 
Body mass index (kg/m2) 27.8 (5.8) 25.1 (4.6) 26.7 (5.5) 
Hypertension 
No 15 408 (53.8) 13 187 (62.5) 28 595 (57.5) 
Yes 13 251 (46.2) 7917 (37.5) 21 168 (42.5) 
Self-reported diabetes 
No 26 424 (91.8) 20 107 (94.8) 46 531 (93.1) 
Yes 2349 (8.2) 1098 (5.2) 3447 (6.9) 
Self-reported IHD 
No 26 991 (93.8) 19 945 (94.1) 46 936 (93.9) 
Yes 1785 (6.2) 1262 (5.9) 3047 (6.1) 
Self-reported cancerb 
No 28 683 (99.7) 21 163 (94.1) 49 847 (97.3) 
Yes 93 (0.3) 44 (0.2) 137 (0.3) 
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Table 1 Continued 
Characteristic Women Men Both sexes 
Haematocrit (%) 
Continuous variable 40.0 (4.1) 43.6 (4.3) 41.5 (4.5) 
Categories 
15–29 313 (1.1) 89 (0.4) 402 (0.8) 
30–34 1955 (6.8) 415 (2.0) 2370 (4.7) 
35–39 10 040 (34.9) 2701 (12.7) 12 741 (25.5) 
40–44 12 987 (45.1) 8931 (42.1) 21 918 (43.9) 
45–49 3286 (11.4) 7509 (35.4) 10 795 (21.6) 
50–54 168 (0.6) 1451 (6.8) 1619 (3.2) 
55–69 27 (0.1) 111 (0.5) 138 (0.3) 
aIHD, ischaemic heart disease. Figures are numbers (column percentages) except for age, body mass
 
index, and haematocrit (continuous variable), for which mean (SD) is reported. Numbers may not add
 
to column totals because of missing data.
 
bExcluding upper gastrointestinal cancer, which was among the exclusion criteria for this study.
 
Table 2 Hazard ratios for mortality according to haematocrit, by sex 
Women Men 
Unadjusted Adjusted Unadjusted Adjusted 
Haematocrit (%) N HR (95% CI) HR (95% CI)a N HR (95% CI) HR (95% CI)a 
Overall mortality 
15–29 15 1.90 (1.13–3.20) 2.12 (1.26–3.58) 18 3.89 (2.42–6.22) 2.12 (1.30–3.45) 
30–34 61 1.28 (0.96–1.68) 1.34 (1.01–1.77) 49 2.35 (1.74–3.16) 1.64 (1.22–2.21) 
35–39 258 1.00 (Referent) 1.00 (Referent) 205 1.47 (1.25-1.74) 1.18 (1.00–1.39) 
40–44 438 1.18 (1.01–1.38) 1.16 (0.99–1.36) 506 1.00 (Referent) 1.00 (Referent) 
45–49 167 1.73 (1.42–2.10) 1.58 (1.29–1.93) 417 0.88 (0.77–1.00) 1.00 (0.88–1.15) 
50–54 13 2.74 (1.57–4.79) 2.05 (1.17–3.60) 100 1.08 (0.87–1.35) 1.29 (1.04–1.61) 
55–69 3 4.83 (1.55–15.07) 5.61 (1.79–17.55) 12 1.53 (0.82–2.85) 1.25 (0.64–2.42) 
CVD mortality 
15–29 7 2.07 (0.97–4.45) 2.60 (1.21–5.60) 12 5.58 (3.12–9.96) 3.08 (1.71–5.55) 
30–34 28 1.36 (0.90–2.05) 1.48 (0.98–2.25) 16 1.67 (1.01–2.78) 1.21 (0.73–2.01) 
35–39 111 1.00 (Referent) 1.00 (Referent) 93 1.43 (1.12–1.82) 1.19 (0.94–1.52) 
40–44 238 1.49 (1.19–1.87) 1.42 (1.13–1.79) 236 1.00 (Referent) 1.00 (Referent) 
45–49 92 2.23 (1.69–2.94) 1.95 (1.47–2.52) 230 1.05 (0.88–1.27) 1.12 (0.93–1.36) 
50–54 
55–69 
}
9 
1 
4.35 (2.28–8.31) 2.87 (1.49–5.52) 63 
7 
1.49 (1.12–1.97) 
1.99 (0.88–4.47) 
1.61 (1.21–2.15) 
1.70 (0.75–3.85) 
Cancer mortality 
15–29 6 3.13 (1.35–7.24) 2.92 (1.26–6.81) 3 2.94 (0.94–9.28) 1.96 (0.62–6.18) 
30–34 17 1.45 (0.85–2.48) 1.45 (0.84–2.53) 15 3.37 (1.96–5.77) 2. 21 (1.27–3.82) 
35–39 63 1.00 (Referent) 1.00 (Referent) 54 1.80 (1.30–2.49) 1.37 (0.98–1.91) 
40–44 90 1.02 (0.74–1.42) 1.08 (0.77–1.50) 112 1.00 (Referent) 1.00 (Referent) 
45–49 23 1.02 (0.63–1.64) 1.05 (0.64–1.71) 63 0.61 (0.44–0.83) 0.74 (0.54–1.03) 
50–54 
55–69 
}
1 
2 
2.33 (0.73–7.44) 2.57 (0.80–8.27) 18 
2 
0.84 (0.51–1.41) 
1.37 (0.34–5.55) 
1.14 (0.68–1.93) 
1.21 (0.30–4.98) 
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CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; N, number of deaths.
 
aHazard ratos (95% CIs) are adjusted for age; ethnicity; place of residence; education level; cigarette smoking (both current/former
 
status and cumulative use); water-pipe smoking; nass chewing; opium use; body mass index; and history of hypertension,
 
self-reported diabetes, ischemic heart disease, and cancer (variables as shown in Table 1).
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Table 3 Sensitivity analyses for association of haematocrit and mortality, by sex 
Women Men 
Haematocrit (%) N HR (95% CI) N HR (95% CI) 
Excluding first 2 years of follow-up 
15–29 6 1.47 (0.65–3.32) 9 1.73 (0.89–3.37) 
30–34 32 1.18 (0.81–1.73) 24 1.31 (0.86–1.99) 
35–39 160 1.00 (Referent) 104 0.94 (0.76–1.18) 
40–44 292 1.19 (0.98–1.44) 337 1.00 (Referent) 
45–49 120 1.72 (1.35–2.19) 265 0.93 (0.79–1.10) 
50–54 
55–69 
}
8 
1 
1.92 (0.98–3.78) 61 
5 
1.16 (0.88–1.53) 
0.83 (0.31–2.24) 
Mortality in never-users of cigarettes, hookahs, or opium 
15–29 12 2.38 (1.32–4.26) 2 0.74 (0.18–3.00) 
30–34 49 1.52 (1.11–2.09) 17 2.25 (1.36–3.70) 
35–39 191 1.00 (referent) 78 1.40 (1.08–1.82) 
40–44 350 1.28 (1.07–1.53) 195 1.00 (Referent) 
45–49 127 1.75 (1.39–2.20) 172 0.94 (0.76–1.16) 
50–54 10 2.28 (1.21–4.34) 53 1.47 (1.08–2.01) 
55–69 2 4.59 (1. 13–18.60) 5 1.98 (0.63–6.18) 
Excluding external causes of death 
15–29 14 2.11 (1.23–3.62) 18 2.21 (1.36–3.61) 
30–34 60 1.40 (1.05-1.86) 48 1.69 (1.25–2.28) 
35–39 242 1.00 (Referent) 197 1.20 (1.01–1.42) 
40–44 417 1.18 (1.00–1.38) 474 1.00 (Referent) 
45–49 163 1.64 (1.34–2.02) 378 0.98 (0.85–1.13) 
50–54 13 2.18 (1.24–3.82) 92 1.28 (1.02-1.61) 
55–69 3 5.96 (1.90–18.68) 12 1.31 (0.68–2.55) 
Excluding individuals with self-reported IHD at baseline 
15–29 11 1.89 (1.03–3.47) 11 1.88 (1.00–3.53) 
30–34 49 1.28 (0.93–1.75) 46 1.95 (1.43–2.66) 
35–39 216 1.00 (Referent) 179 1.25 (1.05–1.50) 
40–44 373 1.20 (1.01–1.42) 415 1.00 (Referent) 
45–49 137 1.58 (1.27–1.97) 349 1.05 (0.90–1.22) 
50–54 11 2.43 (1.32–4.47) 81 1.32 (1.03–1.69) 
55–69 3 10.46 (3.34–32.77) 10 1.14 (0.54–2.43) 
CI, confidence interval; HR, hazard ratio; IHD, ischaemic heart disease; N, number of deaths. 
Hazard ratios (95% CIs) are adjusted for age; ethnicity; place of residence; education level; cigarette smoking 
(both current/former status and cumulative use); water-pipe smoking; nass chewing; opium use; body mass 
index; and history of hypertension, self-reported diabetes, ischemic heart disease, and cancer (variables as 
shown in Table 1). 
Hazard ratios (95% CIs) in never-users of cigarettes, a hookah, or opium were not adjusted for the variables of 
cigarette, hookah, and opium use. 
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the study. The U-shaped relationship was also main­
tained after exclusion of the first 2 years of follow-up 
in the study, done for the purpose of minimizing the 
effect of conditions prevalent at enrollment in the 
study. Similar results were seen when HCT was trea­
ted as a categorical as when it was treated as a con­
tinuous variable. Our results also suggest such a 
U-shaped association between HCT and cancer mor­
tality, but because the number of deaths from cancer 
of study participants with high values of HCT was 
modest, the association in the high HCT direction 
could not be investigated precisely. 
A U-shaped relationship between HCT and mortality 
in specific population groups, including individuals 
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Figure 1 Non-linear risk estimates for the association between haematocrit and mortality.
 
Note. Risk estimates are adjusted for age, ethnicity, place of residence, education level, cigarette smoking (both current/
 
former status and cumulative use), water-pipe smoking, nass chewing, opium use, body mass index, hypertension, and self-

reported diabetes, ischemic heart disease, and cancer (variables as shown in Table 1)
 
with heart failure31,32 or IHD,33 and pregnant 
women, 34 has been observed in a number of studies. 
In the general population, a similar U-shaped rela­
tionship between HCT and some health outcomes 
has also been reported in a few studies done in 
high-income countries,16,35,36 usually with different 
patterns of association in men and women. In one 
such study, restricted to women, in which a high 
HCT was associated with mortality from IHD, a low 
HCT was associated with cancer mortality.16 In the 
Framingham Heart Study, which showed a 
U-shaped association between HCT and CVD mortal­
ity in men and women and between HCT and the 
incidence of CVD in women, 35 the lowest quintiles 
of HCT in men, of 25–44%, and in women, of 
21–39%, also included some ‘normal’ values of HCT 
based on the WHO definition of this haematological 
measure. 26 In a study does as part of the National 
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Figure 2 Non-linear risk estimates for the association between haematocrit and mortality after excluding the first two
 
years of follow-up.
 
Note. Risk estimates are adjusted for age, ethnicity, place of residence, education level, cigarette smoking (both current/
 
former status and cumulative use), water-pipe smoking, nass chewing, opium use, body mass index, hypertension, and self-

reported diabetes, ischemic heart disease, and cancer (variables as shown in Table 1)
 
Health and Nutrition Examination Survey II, which 
had only three levels of HCT, there was a U-shaped 
relationship between HCT and cardiovascular and 
overall mortality among men in unadjusted analyses, 
but these associations disappeared after adjustment 
for risk factors for CVD.36 In women, the same 
study found a linear relationship of HCT with cardio­
vascular mortality and a J-shaped relationship of HCT 
with overall mortality in unadjusted analyses. 
However, upon stratification for age and after adjust­
ment for risk factors for CVD, a high HCT in younger 
women was associated with increased cardiovascular 
mortality whereas a high HCT in older women were 
associated with a decreased risk of overall mortality.36 
A relatively smaller study, of HCT and stroke in rural 
areas of Japan, which also had only 3 categories of 
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Table 4 Associations between haematocrit and selected variables in the baseline cohort 
Women Men 
Adjusted Mean Adjusted Mean 
Characteristic 
Mean 
HCT (SD)a 
(regression 
coefficient)b P-valueb 
Mean 
HCT (SD)a 
(regression 
coefficient)b P-valueb 
Total 39.98 (4.1) 39.97 – 43.56 (4.3) 43.56 – 
Age (years), continuous – [0.011] <0.001 – (–0.061) <0.001 
Ethnicity 
Non-Turkmen 39.86 (4.1) 39.80 Referent 43.46 (4.0) 43.25 Referent 
Turkmen 40.02 (4.1) 40.03 <0.001 43.59 (4.3) 43.66 <0.001 
Place of residence 
Rural 39.83 (4.1) 39.83 Referent 43.26 (4.3) 43.28 Referent 
Urban 40.53 (4.1) 40.50 <0.001 44.87 (4.2) 44.77 <0.001 
Education level 
No school 40.00 (4.1) 40.02 Referent 43.26 (4.4) 43.86 Referent 
Primary school 39.80 (4.1) 39.65 <0.001 43.59 (4.4) 43.35 <0.001 
Middle school 39.62 (4.3) 39.29 <0.001 43.78 (4.2) 43.17 <0.001 
High school/higher 40.18 (3.9) 39.91 0.46 44.31 (4.0) 43.17 <0.001 
P for trend 0.001 <0.001 
Cigarette smoking 
Status 
Never smoker 39.96 (4.1) 39.96 Referent 43.66 (4.2) 43.42 Referent 
Former smoker 40.32 (3.6) 40.16 0.57 42.81 (4.6) 43.28 0.09 
Current light smoker 40.90 (4.4) 41.06 <0.001 43.74 (4.4) 43.94 <0.001 
Current heavy smoker 41.50 (4.2) 41.36 0.01 44.02 (4.6) 44.46 <0.001 
P for trend <0.001 <0.001 
Cumulative use 
None 39.96 (4.1) 39.96 Referent 43.66 (4.2) 43.42 Referent 
1–5 pack-years 40.69 (4.0) 40.78 0.001 43.23 (4.3) 43.40 0.79 
5.1–10 pack-years 40.58 (4.7) 40.43 0.37 43.25 (4.5) 43.56 0.27 
10.1–20 pack-years 41.76 (3.4) 41.66 0.005 43.51 (4.4) 43.83 <0.001 
4 20 pack-years 40.85 (5.0) 40.84 0.17 43.54 (4.8) 44.16 <0.001 
P for trend <0.001 <0.001 
Water-pipe smoking 
Never 39.97 (4.1) 39.96 Referent 43.56 (4.3) 43.55 Referent 
Ever 40.58 (4.3) 40.81 <0.001 44.02 (4.9) 44.46 0.003 
Nass chewing 
Never 39.98 (4.1) 39.97 Referent 43.84 (4.3) 43.65 Referent 
Ever 39.33 (3.8) 39.74 0.32 42.13 (4.3) 43.09 <0.001 
Opium use 
Never 39.96 (4.0) 39.93 Referent 43.97 (4.2) 43.82 Referent 
Ever 40.23 (4.3) 40.47 <0.001 42.55 (4.5) 42.90 <0.001 
BMI (kg/m2), continuous – [0.104] <0.001 – (0.183) <0.001 
Hypertension 
No 39.61 (4.0) 39.75 Referent 43.42 (4.3) 43.45 Referent 
Yes 40.40 (4.1) 40.23 <0.001 43.78 (4.5) 43.73 <0.001 
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Table 4 Continued 
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Women Men 
Adjusted Mean Adjusted Mean 
Characteristic 
Mean 
HCT (SD)a 
(regression 
coefficient)b P-valueb 
Mean 
HCT (SD)a 
(regression 
coefficient)b P-valueb 
Self-reported diabetes 
No 39.91 (4.1) 39.94 Referent 43.54 (4.3) 43.56 Referent 
Yes 40.71 (4.1) 40.33 <0.001 43.83 (4.6) 43.52 0.78 
Self-reported IHD 
No 39.95 (4.1) 39.97 Referent 43.57 (4.3) 43.56 Referent 
Yes 40.37 (4.2) 39.94 0.76 43.34 (4.9) 43.48 0.51 
Self-reported cancer 
No 39.98 (4.1) 39.97 Referent 43.56 (4.3) 43.56 Referent 
Yes 39.52 (4.8) 39.39 0.17 43.41 (6.3) 43.52 0.95 
BMI, body mass index; HCT, haematocrit; IHD, ischaemic heart disease.
 
aMean HCT (SD) is arithmetic mean (standard deviation) of HCT for each category.
 
bFor continuous variables, adjusted regression coefficients are shown. Adjusted means or regression coefficients and corresponding
 
P-values were calculated with multivariate linear regression models, in which haematocrit (as a continuous variable) was the
 
dependent variable, and adjusted for other variables in the table except for cumulative smoking of cigarettes. Adjusted means and
 
P-values for cumulative smoking of cigarettes were adjusted for the other variables but not for cigarette-smoking status.
 
HCT, showed a U-shaped association between HCT 
and death from stroke in women, with the association 
for a low HCT being statistically significant.37 In men, 
there was a non-significantly positive association be­
tween HCT and death from stroke. 
Our results are based on fine categories, and to our 
knowledge, this may be the first reported study of the 
relationship between HCT and mortality from mul­
tiple outcomes across a very wide distribution of 
HCT values for both men and women in the general 
population. However, despite the U-shaped associ­
ations of HCT with mortality in both sexes, the asso­
ciation between high HCT and higher mortality was 
stronger in women than in men, whereas the associ­
ation between low HCT and higher mortality was 
stronger in men. We adjusted our results for several 
confounding factors that might have dissimilar distri­
butions in women and men. The reasons for these sex 
differences in the association between HCT and mor­
tality are not clear. Estrogen is associated with an 
increased risk of vascular thrombosis,38 and meno­
pausal hormone replacement therapy has been asso­
ciated with an increased risk of CVD.39,40 The 
thrombotic effect of estrogen might be more pro­
nounced with a high HCT, which is associated with 
higher blood viscosity. However, the associations be­
tween endogenous estrogen levels and CVD have been 
inconsistent.41–44 Further investigations are needed of 
sex differences in the association between HCT and 
mortality. 
It is well established that an increased HCT in­
creases the risk of CVD and mortality from CVD35 
In a meta-analysis of 16 population-based prospective 
studies done mainly in Europe and North America, 
Danesh and colleagues estimated an overall relative 
risk of 1.16 (95% CI 1.05–1.29) for coronary heart 
disease (CHD) in a comparison of the top tertile of 
HCT (mean HCT ¼ 46.3%) with the bottom tertile 
(mean HCT ¼ 41.7%).14 In three studies of people 
with pre-existing CVD, the relative risk (RR) of mor­
tality was higher for those with higher values of HCT 
(RR ¼ 1.81; 95% CI 1.19–2.76). The associations of 
increased HCT with CHD and CVD have been con­
firmed in studies published since Danesh et al. 
meta-analysis.15,36,45 The association between elevated 
HCT and death may merely reflect the effects of 
smoking, which is known to raise HCT values.46 On 
the other hand, it is also plausible that a high HCT 
enhances acute thrombosis. In fact, experimental stu­
dies have shown that lower values of HCT are asso­
ciated with a lower rate of arterial thrombosis.47 This 
is in agreement with the finding of an enhanced ad­
hesion of platelets to the vascular endothelial wall 
with increasing HCT.48 The persistence of the associ­
ation between both low and high values of HCT and 
mortality in our study among never-smokers and after 
adjustments for the smoking of cigarettes and use of 
other tobacco products supports the independence 
from smoking of the associations observed in our 
study. 
Studies of specific groups with an increased risk of 
anaemia have shown associations between low values 
of HCT and mortality. Such groups include pregnant 
women (mainly in low- to middle-income coun­
tries)49; the elderly2,3,50; patients with chronic 
kidney disease,4 heart failure,6,7 or CHD51; and those 
susceptible to acute hemodynamic changes, including 
individuals with hip fracture52 or pulmonary embol­
ism.53 Prolonged tissue hypoxia may have a role in 
the association between anaemia and increased 
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mortality.54,55 Anaemia may have organ-specific ef­
fects. For example, it may contribute to CVD through 
an increased cardiac preload, reduced afterload, or 
increased cardiac output, with left-ventricular hyper­
trophy as a long-term consequence.54 Anaemia is gen­
erally associated with elevated levels of erythropoietin 
(EPO), which have effects on cardiovascular system 
that range from protective to adverse.56 Therefore, 
some of the health outcomes associated with anaemia 
may be related to effects of excess EPO. Furthermore, 
anaemia is sometimes to the result of nutritional defi­
ciencies,57,58 which may be more prevalent in low- to 
middle-income regions,59 including Golestan Province, 
than in areas with higher incomes.60 The anaemia in 
these regions may also be accompanied by the risk of 
other consequences of nutritional deficiencies.7,49 The 
results of the present study are particularly relevant 
for low- and middle-income regions in which ana­
emia is common and in which there is a substantial 
population with suboptimal levels of HCT. According 
to the WHO Vitamin and Mineral Nutrition Informa­
tion System for 1993–2005, approximately 42% and 
25% of the populations in the low- and 
middle-income countries, respectively, were reported 
to be anemic, representing 367 million and 1.1 billion 
individuals, respectively.61 
It might be argued that the association between low 
and high HCT and mortality is related to the associ­
ation of HCT with risk factors for CVD and perhaps 
for other diseases. Our results confirm a positive as­
sociation of HCT with such other risk factors for CVD 
as cigarette smoking, obesity, hypertension, and 
diabetes (among women). However, the association 
between HCT and mortality in our study persisted 
after adjustments for these other risk factors, suggest­
ing an independent association of HCT with CVD. 
Nevertheless, we did not have data on cholesterol 
levels, and a history of diabetes was in our study 
based on self-reports. Further studies of the associ­
ation between HCT and increased mortality, and the 
potential mechanistic factors for this association, are 
required. 
The results of this study may have applications in in 
public health and disease prevention. First, individ­
uals with low and high values of HCT, as an indicator 
of a higher risk of death, may be monitored regularly 
for common life-threatening conditions, including 
CVD. Regular monitoring of risk factors for CVD in 
persons with high values of HCT might also be con­
sidered because of the possible association of a high 
HCT with many other risk factors of CVD. Also, if a 
causal association is established between low values 
of HCT and overall mortality, correction of anaemia in 
the general population may be considered more ser­
iously by the public, physicians, and health systems, 
particularly in low- and middle-income countries, 
where anaemia is more common. Results of our 
study support the need for further studies of any 
effects of reducing body-iron stores in reducing 
mortality in the general population. A beneficial 
effect of regular phlebotomy in decreasing overall 
mortality in patients with peripheral artery disease, 
especially in younger patients who had better compli­
ance with phlebotomy and higher blood ferritin levels 
at entry, has been reported in a randomized multi-
center trial.62,63 However, the results of observational 
studies of voluntary blood donation and health out­
comes, including diabetes, cardiac events, and cancer, 
are mixed, with some such studies reporting a bene­
ficial association64–66 and others finding no associ­
ation.67–70 
Our study has several strengths, including 
comprehensive and standardized follow-up of a large 
community-based cohort in a middle-income country, 
with the inclusion of both rural and urban partici­
pants; the inclusion of a wide range of HCT values; 
the availability of overall and subtype mortality data; 
and examination of the associations of HCT with 
disease and mortality in different models using con­
tinuous and categorical data. Limitations of the study 
include a self-reported history of diabetes, IHD, and 
cancer; a lack of data on blood lipids and other cel­
lular blood components; and the unavailability of data 
on incident disease and other outcomes of interest 
(e.g. hospitalization and major cardiovascular 
events). Furthermore, we used a single measurement 
of HCT, whereas the normal range of HCT is subject 
to many day-to-day variables. However, we believe 
that the latter issue is not a major drawback for our 
study, because: (i) except for acute cases of 
hemodynamic changes, the day-to-day variation in 
HCT is likely to be small; and (ii) any measurement 
error in our prospective study is likely to be 
non-differential and to reduce the apparent associ­
ation between high or low HCT and mortality. 
Hence, we conclude that this type of misclassification 
of exposure is unlikely to reverse the true trend of the 
association of low and high values of HCT with mor­
tality.71 Furthermore, the association with mortality 
of low and high values of HCT obtained from single 
measurements can also be important per se, because 
these HCT levels are those usually measured in clin­
ical practice. Additionally, the distribution of HCT 
values might differ in participants and non­
participants in the study. We cannot examine this 
because we do not have HCT values for non­
participants. However, with regard to the potential 
role of non-participation on the observed associations, 
these associations could have arisen spuriously if 
non-participants with low or high HCT had much 
greater longevities or non-participants with normal 
values of HCT had much shorter longevities than par­
ticipants with similar HCT levels. Both scenarios seem 
unlikely. 
In conclusion, we report a U-shaped relationship 
between HCT and mortality in which both low and 
high values of HCT are associated with increased over­
all mortality as well as with increased mortality from 
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CVD and cancer. We have been able to demonstrate 
this relationship across a very wide range of HCT 
values for both men and women. These results are of 
particular importance for other low- and middle-
income countries, where a substantial proportion of 
the population has suboptimal values of HCT. 
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KEY MESSAGES 
•	 Few studies have investigated the correlation between a wide range of low and high values of 
haematocrit (HCT) and mortality in the general population. 
•	 We found a U-shaped relationship between categories of HCT and mortality in both sexes, with both 
low and high values of HCT being associated with increased overall mortality. 
•	 These results may be of particular importance for low- and middle-income countries, where a sub­
stantial proportion of the population lives with suboptimal values of HCT. 
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